A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen
Article Abstract:
A pilot study evaluates the safety and noninferiority and explores the efficacy of administration of once-daily versus twice-daily lopinavir/ritonavir (LPV/r) in antiretroviral-naive HIV-1-infected subjects. During 48 weeks, a once-daily regimen of lopinavir/ritonavir + tenofovir disoproxil fumarate + emtricitabine appears to contain similar virologic and immunologic responses in antiretroviral-naive subjects as the same region with lopinavir/ritonavir administered twice daily.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect
Article Abstract:
The bioavailability of tablet doses of lopinavir/ritonavir at 800/200 mg or 400/100 mg under different meal conditions are assessed and compared with equal doses of the soft-gelatin capsule (SGC) after a moderate-fat meal. The findings reveal that the diminished food effect and decreased variability of the tablet have resulted in more consistent lopinavir and ritonavir exposures, thereby minimizing the likelihood of extreme high or low values compared with the SGC.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)
Article Abstract:
The maintenance with Iopinavir/ritonavir monotherapy vs. continuing Iopinavir/ritonavir and 2 nucleosides in Human Immunodeficiency Virus (HIV)-infected patients with suppresses HIV replication is evaluated. The results reveal that the failure of Iopinavir/ritronavir monotherapy are not associated with the development of primary resistance mutations in the protease gene and could be successfully reinduced adding back prior nucleosides.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy
- Abstracts: Blood pressure. Standards for clinical practice and staff training in CPR. Development of a guide for neurological observations
- Abstracts: Nurses debate merits of new mental health plans. Being sensitive to spiritual beliefs is part of holistic care
- Abstracts: Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis. Role of lymphocyte multidrug resistance protein 1 in HIV infection: Expression, function, and consequences of inhibition
- Abstracts: The effect of indomethacin and prostacyclin agonists on blood pressure in a rat model of preeclampsia. Comparing uterine electromyography activity of antepartum patients versus term labor patients